Oncotype DX is a genomic test that analyses 21 genes in the tumour to produce a recurrence score. That score informs one of the most delicate decisions in early breast cancer: which hormone-receptor-positive, HER2-negative patients benefit from adjuvant chemotherapy and which can safely avoid it.
What was known
The test was developed in 2004 and has since become a routine tool in practice. It quantifies the expression of 21 genes and turns the result into an estimate of distant recurrence risk, refining prognosis beyond classic factors such as tumour size, nodal status or histological grade. Multiple studies have progressively validated its reliability and clinical utility across different settings.
What this work adds
This is a review that synthesises the accumulated evidence on the clinical utility of Oncotype DX, describes its evolving applications and points to where its future use in precision oncology is heading. It does not present new patient data, but rather an ordered update of what has been published so far and of the open lines of research.
Main results
According to the review, the test enables more precise risk stratification and individualised treatment planning, helping to reduce exposure to unnecessary chemotherapy and improve patient outcomes. Leading scientific societies such as the American Society of Clinical Oncology and the National Comprehensive Cancer Network have already incorporated it into their clinical guidelines. Beyond its established role in the adjuvant chemotherapy decision, its potential use is being investigated in broader contexts: node-positive breast cancer, neoadjuvant therapy, radiotherapy and ductal carcinoma in situ. The review also points to ongoing technological advances, such as artificial intelligence-based predictive models and the identification of new biomarkers, which could improve its accuracy and expand its applications.
What it means
For someone diagnosed with early hormone-receptor-positive breast cancer, this tool is part of the information the team can use to tailor treatment to their specific case rather than applying a uniform criterion. The review stresses that the test does not replace clinical judgement or tumour assessment, but adds a layer of genomic information that feeds into the decision. It also makes clear that its applications remain under study and that not all scenarios are settled: the data on node-positive disease, neoadjuvant therapy or carcinoma in situ are the subject of active research, not closed recommendations.
Reading from the breast unit
The spread of these genomic platforms reinforces the role of multidisciplinary decision-making in the breast unit: the test result is one more element that the committee weighs alongside pathology and the patient’s situation. Having agile access to these assays and homogeneous criteria for requesting them is, in practice, a matter of quality of care and of equity between centres.
Reference: Yang RL, Liang Y, et al. Oncotype DX: Clinical Utility, Evidence, and Future Trends in Personalized Breast Cancer Management. International Journal of Cancer, 2026. DOI
